Show simple item record

dc.contributor.authorSaad, F.
dc.contributor.authorArmstrong, A. J.
dc.contributor.authorThiery-Vuillemin, A.
dc.contributor.authorOya, M.
dc.contributor.authorShore, N. D.
dc.contributor.authorProcopio, G.
dc.contributor.authorArslan, C.
dc.contributor.authorMehra, N.
dc.contributor.authorParnis, F.
dc.contributor.authorBrown, E.
dc.contributor.authorSchlurmann, F. C.
dc.contributor.authorJoung, J. Y.
dc.contributor.authorSugimoto, M.
dc.contributor.authorSartor, O.
dc.contributor.authorLiu, Y. Z.
dc.contributor.authorPoehlein, C. H.
dc.contributor.authorDesai, C.
dc.contributor.authorDel Rosario, P. M. D.
dc.contributor.authorClarke, Noel W
dc.date.accessioned2023-01-24T10:32:25Z
dc.date.available2023-01-24T10:32:25Z
dc.date.issued2022en
dc.identifier.citationSaad F, Armstrong AJ, Thiery-Vuillemin A, Oya M, Shore ND, Procopio G, et al. Biomarker analysis and updated results from the Phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology. 2022 Sep;33(7):S1160-S. PubMed PMID: WOS:000866211601614.en
dc.identifier.doi10.1016/annonc/annonc1070en
dc.identifier.urihttp://hdl.handle.net/10541/625972
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/annonc/annonc1070en
dc.titleBiomarker analysis and updated results from the Phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentDepartment Of Urology, Centre Hospitalier de l’Université de Montréal/CRCHUM, Université de Montreal, H2X 3J4en
dc.identifier.journalAnnals of Oncologyen
dc.description.noteen]


Files in this item

This item appears in the following Collection(s)

Show simple item record